glp 1 parkinson's disease and neuroprotection A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular and neurodegenerative disorders Dual GLP-1 and GIP Agonist

The averages in clinical trials run by the drugs manufacturer were: Wegovy (injection): 15% weight loss in 68 weeks Wegovy (pill): 14% weight loss in 64 weeks Ozempic: 7% weight loss in 30 weeks Rybelsus: 4% weight loss in 6 months These statistics are from clinical trials, where the research team controls many of the variables

The results of the study indicated that these individuals had a more than fourfold increased risk of developing asthma compared to those without AHR, suggesting that AHR is an important risk factor for the development of airway disease [59]

Sample GH stack: IGF-1 LR3: 40-60 mcg post-workout CJC-1295 (no DAC): 100 mcg before bed Ipamorelin: 100-200 mcg before bed Duration: 4-6 weeks IGF-1 LR3, GH peptides can run longer The Sermorelin peptide offers another GH-releasing option for those seeking alternatives to CJC-1295

Heres some interesting data from a study where participants used Phentermine for six months

Nails grow faster and may feel stronger, a secondary indicator of systemic collagen metabolism improvement

Diamide-treated monothiol PfGrx C32S/C88S was intended as a negative control but had a detectable activity with roGFP2 WT (SH) 2 with a rate constant k ox around 6.5 10 2 M 1 s 1 (Fig